Quick Summary What it is: A synthetic peptide that activates three receptors at once GLP-1, GIP, and glucagon
While the pill helped patients lose roughly 11% of their body weight during the clinical trial period, thats still lower than the shot form Wegovy, according to Morgan Stanley analysts
Racial/ethnic disparities in weight bias and stigma have also been documented in healthcare settings and may affect GLP-1 access
In people with T2D, 48% of the participants achieved 10% WL after 26 weeks of treatment with orforglipron 45 mg in a phase 2 trial (Fig
Our guide on foods to avoid on tirzepatide identifies the biggest culprits
Below is a summary (definitely not exhaustive) for the landscape of weight loss drugs in development (including company name and formulation, dosing and mechanism), showing my estimation of when these could launch and become available for patients